Where it comes from

Made in
The same neurons as NPW-23
Sent out by
With NPW-23
Acts on
  • Hypothalamus
  • Brainstem

What it does

  • Acts at both receptors, a little less strongly than NPW-23 1
  • The two forms come from one cut or two at the precursor’s end, and tissue holds both 3
  • Studied in feeding and pain, almost always beside the shorter form rather than instead of it 2

In medicine

  • No medicine copies it or blocks it, and it is not measured in people
  • Nothing in the clinic would distinguish it from NPW-23: both act at the same two receptors, and no selective ligand for either receptor is in use 2

Beyond the body’s own use

  • Nothing containing it is in trials, approved or obtainable outside the laboratory
  • Its difference from NPW-23 is seven residues at one end and a modest loss of potency; no effect has been found that one has and the other does not 1
  • What is unknown is why the longer form exists. Which of the two a tissue releases depends on how far the processing enzymes go, and no condition has been found that shifts that balance, so the ratio has never been shown to mean anything 3

Sources

  1. Shimomura et al., Identification of neuropeptide W as the endogenous ligand for GPR7 and GPR8, Journal of Biological Chemistry 2002
  2. Singh & Davenport, Neuropeptide B and W, neurotransmitters in an emerging receptor system, British Journal of Pharmacology 2006
  3. Tanaka et al., Characterization of a family of endogenous neuropeptide ligands for GPR7 and GPR8, PNAS 2003

This card describes what a medicine is for and what the evidence says; it recommends nothing. Talk to your clinician about anything you read here.